AVE 0.00% 0.3¢ avecho biotechnology limited

pfizer considers t/o of agila specialties, page-11

  1. 2,314 Posts.
    lightbulb Created with Sketch. 47
    cancel as their patents expire...$2b to start again - couldnt they just do that without a t/o? I agree that cancellations occur but I do not think this type of premium would be paid just to cancel new tech and IP imo.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.